TY - JOUR
T1 - Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients
AU - Molmenti, Ernesto P.
AU - Netto, George J.
AU - Murray, Natalie G.
AU - Smith, Douglas M.
AU - Molmenti, Hebe
AU - Crippin, Jeffrey S.
AU - Hoover, Tyrone C.
AU - Jung, Ghapjoong
AU - Marubashi, Shigeru
AU - Sanchez, Edmund Q.
AU - Gogel, Brian
AU - Levy, Marlon F.
AU - Goldstein, Robert M.
AU - Fasola, Carlos G.
AU - Gonwa, Thomas A.
AU - Klintmalm, Goran B.
PY - 2002
Y1 - 2002
N2 - We prospectively collected data on 1,429 liver transplant recipients between December 1984 and December 1998. Fifty-five patients (3.8%; 10 men, 45 women; median age, 44.5 ± 13 [SD] years) with autoimmune hepatitis (AIH) underwent orthotopic liver transplantation (OLT). Transplant recipients with AIH were younger, more likely to be women, and had a greater likelihood of rejection in the first 3, 6, and 12 months. There was no difference in patient survival or graft survival. There were 11 biopsy-proven recurrences (1 man, 10 women) of AIH after OLT. Almost half the episodes occurred within the first year after OLT. No patient required re-OLT because of recurrent disease. AIH has an incidence of 4% and a recurrence rate of 20% in OLT. Transplant recipients are more likely to be young women and have an increased incidence of acute cellular rejection (ACR) during the first post-OLT year. Recurrence should be suspected in those with abnormal liver function test results in the absence of ACR, especially during the first year after OLT. We cannot establish with certainty whether the observed process represents recurrence of the original autoimmune disease, an alloimmune phenomenon, or allograft dysfunction mimicking AIH.
AB - We prospectively collected data on 1,429 liver transplant recipients between December 1984 and December 1998. Fifty-five patients (3.8%; 10 men, 45 women; median age, 44.5 ± 13 [SD] years) with autoimmune hepatitis (AIH) underwent orthotopic liver transplantation (OLT). Transplant recipients with AIH were younger, more likely to be women, and had a greater likelihood of rejection in the first 3, 6, and 12 months. There was no difference in patient survival or graft survival. There were 11 biopsy-proven recurrences (1 man, 10 women) of AIH after OLT. Almost half the episodes occurred within the first year after OLT. No patient required re-OLT because of recurrent disease. AIH has an incidence of 4% and a recurrence rate of 20% in OLT. Transplant recipients are more likely to be young women and have an increased incidence of acute cellular rejection (ACR) during the first post-OLT year. Recurrence should be suspected in those with abnormal liver function test results in the absence of ACR, especially during the first year after OLT. We cannot establish with certainty whether the observed process represents recurrence of the original autoimmune disease, an alloimmune phenomenon, or allograft dysfunction mimicking AIH.
UR - http://www.scopus.com/inward/record.url?scp=0036276895&partnerID=8YFLogxK
U2 - 10.1053/jlts.2002.32981
DO - 10.1053/jlts.2002.32981
M3 - Article
C2 - 12037782
AN - SCOPUS:0036276895
SN - 1527-6465
VL - 8
SP - 519
EP - 526
JO - Liver Transplantation
JF - Liver Transplantation
IS - 6
ER -